Form 4: Xencor Inc. Executive Reports Stock Transactions
SEC Form 4 Filing
John R. Desjarlais, SR. VICE PRESIDENT & CSO of Xencor Inc., reports acquisition and disposition of common stock and stock options.
Summary
- On March 5, 2024, John R. Desjarlais, SR. VICE PRESIDENT & CSO of Xencor Inc. [XNCR], reported transactions involving Xencor's common stock and stock options.
- Desjarlais disposed of 6,629 shares of common stock at a price of $23.429 per share to cover withholding taxes upon the vesting of restricted stock units.
- He also acquired 20,724 shares of common stock through restricted stock units at $0.
- Following these transactions, Desjarlais directly owns 187,713 shares of Xencor common stock.
- Additionally, Desjarlais acquired 124,346 stock options with an exercise price of $22.85, vesting over four years from March 5, 2024, and expiring on March 4, 2034.
- After the transaction, Desjarlais directly owns 124,346 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the document primarily reports routine stock transactions related to executive compensation. There are no explicit positive or negative indicators.
Positives
- The acquisition of restricted stock units and stock options indicates confidence in the company's future performance.
Negatives
- The sale of shares to cover withholding taxes, while routine, slightly reduces the executive's holdings.
Risks
- There are no specific risks highlighted in this document, as it primarily reports stock transactions.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock units and stock options suggests a long-term commitment from the executive.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices and insider activity.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning executive incentives with shareholder value.
- Companies like Amgen, Regeneron, and Gilead Sciences also utilize similar compensation structures for their executives.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of stock and derivative transactions. |
| 03/05/2024 | Vesting Commencement Date for stock options. |
| 03/04/2034 | Expiration date for stock options. |
| 03/06/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.